SUSTAIN-7 (N=1,201), a head-to-head trial against dulaglutide, reported mean weight loss of 5.5 to 7.3 kg at the 1 mg dose over 40 weeks, with A1C reductions of 1.8% from a baseline of approximately 8.2% 3
Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial
By targeting GLP-1, GIP, and glucagon receptors, retatrutide suppresses appetite, delays gastric emptying, and increases energy expenditure
Noom Microdose GLP-1 Rx Plus Program : Starts at $79
doi: 10.1056/NEJMoa1603827 11 MarsoSPBainSCConsoliAEliaschewitzFGJdarELeiterLAet al
For the future, we hope GLP-1- based drugs together with antithrombotic medications can be a promising field to improve prevention and management of coronary events, also in nondiabetic patients, resulting in reduced mortality in patients with CAD